extensive post-market safety data Advantage : Tirzepatide Liver Fat Reduction# Retatrutide : Significant hepatic fat reduction via glucagon receptor activation (up to 82% reduction) Tirzepatide : Moderate hepatic fat reduction observed in trials Advantage : Retatrutide Dosing Convenience# Retatrutide : Once-weekly subcutaneous injection Tirzepatide : Once-weekly subcutaneous injection with established titration schedule Advantage : Neither (tie) Summary and Verdict# Tirzepatide is the proven choice with FDA approval and extensive clinical data

( B O ) Flow cytometry analysis of CD45 + cells ( B ), neutrophils ( C ), Ly6G hi monocytes ( D ), total macrophages ( E ), CD206 + CD301b + M2 macrophages ( F ), Arg + M2 macrophages ( G ), iNOS + M1 macrophages ( H ), CD45 + CD4 + T cells ( I ), Gata3 Th2 cells ( J ), Rort Th17 cells ( K ), T-bet Th1 cells ( L ), Foxp3 + Tregs ( M ), IL-17 + Tregs ( N ), and Rort + Foxp3 + Tregs ( O ) in eWAT of 18- to 22-week-old male WT and Bbs5 / mice ( n = 46 per group)
In this case, the efficacy is not known
Read on for more on what that means, how clinical trials work, who may qualify, and what to do if a trial isnt an option for you (spoiler alert: you have options!)
Meanwhile, the content of intestinal metabolite butyrate was compared to reflect the regulatory effects of these three drugs on gut microbiota